Andrea Arfe, PhD

Assistant Attending Biostatistician
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Career Opportunities
Educational Opportunities
Departmental Newsletter

Andrea Arfe, PhD

Assistant Attending Biostatistician
Share
Share
Andrea Arfe

Email

arfea@mskcc.org

Education

Bocconi University; Milan, Italy

Current Research Interest

Dr. Arfè collaborates with investigators from the MSK Thoracic Oncology Service to study the prognosis of lung cancer patients belonging to rare molecularly-defined subgroups, as well as to design and implement Phase II clinical trials of novel targeted therapies for advanced lung cancer.  He also collaborates with members of the Genito-Urinary Oncology Service in the design and analysis of adaptive and group-sequential clinical trials of new therapies for localized high-risk or metastatic castrate-resistant prostate cancer. In his methodological research, Dr. Arfè aims to develop new adaptive phase II trial designs that leverage data across patient subgroups or auxiliary variables to increase the study efficiency. He is also interested in the development of Reinforcement Learning methods for developing decision rules for monitoring the temporal evolution of blood-based biomarkers of tumor progression.

Publications

Selected peer-reviewed publications:

  1. Arfè A, Narang C, DuBois SG, Reaman G, Bourgeois F. Clinical development of new drugs for adults and children with cancer, 2010-2020. JNCI 2023; 115(8):917-925
  2. Han L, Arfe A, Trippa L. Sensitivity Analyses of Clinical Trial Designs: Selecting Scenarios and Summarizing Operating Characteristics. Am Stat 2023; in press.
  3. Arfè A, Muliere P. A general Bayesian bootstrap for censored data based on the beta-Stacy process. J Stat Planning and Inference 2023; 222:241-251.
  4. Barnett ES, Schultz N, Stopsack KH, Lam ET, Arfè A, Lee J, Zhao JL, Schonhoft JD, Carbone EA, Keegan NM, Wibmer A, Wang Y, Solit DB, Abida W, Wenstrup R, Scher HI. Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer. European Urology 2022; 83(2):112-120
  5. Arfè A, Alexander B, Trippa L. Optimality of testing procedures for survival data. Biometrics 2021; 77:587-598.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Andrea Arfe discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures